Skip to main content
Intended for healthcare professionals

Abstract

Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the present study was to investigate this in patients with generalized social anxiety disorder (SAD) using functional neuroimaging. Regional cerebral blood flow (rCBF) at rest was measured twice using (99m)Tc-ECD SPECT in 10 treatment-naïve patients with SAD. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping. Relative to placebo, CBD was associated with significantly decreased subjective anxiety (p < 0.001), reduced ECD uptake in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus (p < 0.001, uncorrected), and increased ECD uptake in the right posterior cingulate gyrus (p < 0.001, uncorrected). These results suggest that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas.

Get full access to this article

View all access and purchase options for this article.

References

Afifi AK, Bergman RA. (1998) Functional Neuroanatomy: Text and Atlas. New York: McGraw-Hill.
Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. (1981) Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37: 1090–1092.
Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, et al. (1986) Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38: 21–43.
Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852.
Blanco C, Antia SX, Liebowitz MR. (2002) Pharmacotherapy of social anxiety disorder. Biol Psychiatry 51: 109–120.
Bond A, Lader M. (1974) The use of analogues scale in rating subjective feelings. Br J Med Psychol 47: 211–218.
Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, et al. (2008) Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966–973.
Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. (2002) rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52: 126–135.
Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS. (1999) Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 156: 1787–1795.
Brett M, Johnsrude IS, Owen AM. (2002) The problem of functional localization in the human brain. Nat Rev Neurosci 3: 243–249.
Buckner JD, Bonn-Miller MO, Zvolensky MJ and Schmidt NB (2007) Marijuana use motives and social anxiety among marijuana-using young adults. Addict Behav 32: 2238–2252.
Buckner JD, Schmidt NB, Bobadilla L and Taylor J (2006) Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther 44: 1007–1015.
Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM. (2008) Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 42: 230–239.
Bystritsky A, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. (2001) Functional MRI changes during panic anticipation and imagery exposure. Neuroreport 12: 3953–3957.
Campos AC, Guimarães FS. (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199: 223–230.
Cannistraro PA, Rauch SL. (2003) Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull 37: 8–25.
Carey PD, Warwick J, Niehaus DJ, van der Linden G, van Heerden BB, Harvey BH, et al. (2004) Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 4: 30–30.
Carlini EA, Masur J, Magalhães CCPB. (1979) Possível efeito hipnótico do cannabidiol no ser humano. Estudo preliminar. Ciência e Cultura 31: 315–322.
Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. (2000) Psychometric properties of Social Phobia Inventory (SPIN). Br J Psychiatry 176: 379–386.
Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40: 701–708.
Crippa JA, de Lima Osório F, Del-Bem CM, Filho AS, da Silva Freitas MC, Loureiro SR. (2008) Comparability between telephone and face-to-face structured clinical interview for DSM-IV in assessing social anxiety disorder. Perspect Psychiatr Care 44: 241–247.
Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnier R, Ferrari L, et al. (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29: 417–426.
Crippa JAS, Zuardi AW, Hallak JEC. (2010) Therapeutical use of the cannabinoids in psychiatry. Rev Bras Psiquiatr 32(Suppl I): S56–S66.
Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. (2009) Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24: 515–523.
Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175–185.
Davidson JR. (2003) Pharmacotherapy of social phobia. Acta Psychiatr Scand 417: 65–71.
Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, et al. (1991) The Brief Social Phobia Scale. J Clin Psychiatry 52: 48–51.
De Lima Osório F, Crippa JA, Loureiro SR. (2007) A study of the discriminative validity of a screening tool (MINI-SPIN) for social anxiety disorder applied to Brazilian university students. Eur Psychiatry 22: 239–243.
Di Piero V, Ferracuti S, Sabatini U, Tombari D, Di Legge S, Pantano P, et al. (2001) Diazepam effects on the cerebral responses to tonic pain: a SPET study. Psychopharmacology (Berl) 158: 252–258.
Doronbekov TK, Tokunaga H, Ikejiri Y. (2005) Neural basis of fear conditioning induced by video clip: positron emission tomography study. Psychiatry Clin Neurosci 59: 155–162.
Eser D, Leicht G, Lutz J, Wenninger S, Kirsch V, Schüle C, et al. (2009) Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. Hum Brain Mapp 30: 511–522.
Etkin A, Wager TD. (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164: 1476–1488.
Ferrari MC, Busatto GF, McGuire PK, Crippa JA. (2008) Structural magnetic resonance imaging in anxiety disorders: an update of research findings. Rev Bras Psiquiatr 30: 251–264.
Fischer H, Wik G, Fredrikson M. (1996) Functional neuroanatomy of robbery re-experience: affective memories studied with PET. Neuroreport 7: 2081–2086.
Freitas-Ferrari MC, Hallak JE, Trzesniak C, Filho AS, Machado-de-Sousa JP, Chagas MH, et al. (2010) Neuroimaging in social anxiety disorder: A systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 34: 565–580.
Freund TF, Katona I, Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017–1066.
Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2: 189–210.
Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. (1996) Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 4: 223–235.
Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, et al. (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58: 132–142.
Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95–105.
Gaetani S, Cuomo V, Piomelli D. (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9: 474–478.
Giordani B, Boivin MJ, Berent S, Betley AT, Koeppe RA, Rothley JM, et al. (1990) Anxiety and cerebral cortical metabolism in normal persons. Psychiatry Res 35: 49–60.
Grey SJ, Price G, Mathews A. (2000) Reduction of anxiety during MR imaging: a controlled trial. Magn Reson Imaging 18: 351–355.
Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100: 558–559.
Guimarães FS, Kohem CL, Gus G, Fillmann HS, de-Vecino MC, de-Paoli CL, et al. (1989) A simple simulated public speaking test for evaluating anxiolytic drugs. Braz J Med Biol Res 22: 1083–1089.
Gur RC, Gur RE, Resnick SM, Skolnick BE, Alavi A, Reivich M. (1987) The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab 7: 173–177.
Hallak JEC, Crippa JAS, Quevedo J, Roesler R, Schröder N, Nardi AE, et al. (2010) National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the field of translational medicine and mental health. Rev Bras Psiquiatr 32: 83–90.
Hoehn-Saric R, Lee JS, McLeod DR, Wong DF. (2005) Effect of worry on regional cerebral blood flow in nonanxious subjects. Psychiatry Res 140: 259–269.
Hou C, Liu J, Wang K, Li L, Liang M, He Z, et al. (2007) Brain responses to symptom provocation and trauma-related short-term memory recall in coal mining accident survivors with acute severe PTSD. Brain Res 1144: 165–174.
Kilts CD, Kelsey JE, Knight B, Ely TD, Bowman FD, Gross RE, et al. (2006) The neural correlates of social anxiety disorder and response to pharmacotherapy. Neuropsychopharmacology 31: 2243–2253.
Liotti M, Mayberg HS, Brannan SK, McGinnis S, Jerabek P, Fox PT. (2000) Differential limbic–cortical correlates of sadness and anxiety in healthy subjects: implications for affective disorders. Biol Psychiatry 48: 30–42.
McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ. (1994) Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry 164: 459–468.
MacLean PD. (1993) Perspectives on cingulate cortex in the limbic system. In: Vogt BA, Gabriel M (eds) Neurobiology of Cingulate Cortex and Limbic Thalamus. Basel, Boston: Birkhäuser, 1–15.
Maddock RJ, Buonocore MH, Kile SJ, Garrett AS. (2003) Brain regions showing increased activation by threat-related words in panic disorder. Neuroreport 14: 325–328.
Maddock RJ. (1999) The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Trends Neurosci 22: 310–316.
Malizia AL. (1999) What do brain imaging studies tell us about anxiety disorders? J Psychopharmacol 13: 372–378.
Maltby N, Tolin DF, Worhunsky P, O’Keefe TM, Kiehl KA. (2005) Dysfunctional action monitoring hyperactivates frontal-striatal circuits in obsessive-compulsive disorder: an event-related fMRI study. Neuroimage 24: 495–503.
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534.
Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE. (1999) Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 100: 67–75.
Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. (1992) Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12: 750–758.
Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. (1995) A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 2: 89–101.
McLellan AT, Luborsky L, O’Brien CP, Woody GE. (1980) An improved diagnostic instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis 168: 26–33.
Mechoulam R, Hanus L. (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121: 35–43.
Moreira FA, Aguiar DC, Guimarães FS. (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30: 1466–1471.
Musty RE, Conti LH and Mechoulam R (1984) Anxiolytic properties of cannabidiol. In: Harvey DJ, (eds) Marihuana ‘84. Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Limited, 713–719.
Norris H. (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181–191.
Onaivi ES, Green MR, Martin BR. (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002–1009.
Osório FL, Crippa JAS, Loureiro SR. (2006) Cross-cultural validation of the Brief Social Phobia Scale for use in Portuguese and the development of a structured interview guide. Rev Bras Psiquiatr 28: 212–217.
Osório F, de L, Crippa JA, Loureiro SR. (2009) Cross-cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency. Rev Bras Psiquiatr 31: 25–29.
Osório FL, Crippa JA, Loureiro SR. (2010) Study of the psychometric qualities of the Brief Social Phobia Scale (BSPS) in Brazilian university students. Eur Psychiatry 25: 178–188.
Osuch EA, Benson B, Geraci M, Podell D, Herscovitch P, McCann UD, et al. (2001) Regional cerebral blood flow correlated with flashback intensity in patients with posttraumatic stress disorder. Biol Psychiatry 50: 246–253.
Paquette V, Lévesque J, Mensour B, Leroux JM, Beaudoin G, Bourgouin P, et al. (2003) “Change the mind and you change the brain”: effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 18: 401–409.
Pertwee RG. (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199–215.
Pickens JT. (1981) Sedative activity of cannabis in relation to its Δ9- tetrahydrocannabinol and cannabidiol content. Br J Pharmac 72: 649–656.
Prasko J, Horácek J, Záleský R, Kopecek M, Novák T, Pasková B, et al. (2004) The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuro Endocrinol Lett 25: 340–348.
Rakhshan F, Day TA, Blakely RD and Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292: 960–967.
Rauch SL, Dougherty DD, Cosgrove GR, Cassem EH, Alpert NM, Price BH, et al. (2001) Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry 50: 659–667.
Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA. (2002) Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27: 782–791.
Reichenberg A, Harvey PD. (2007) Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. Psychol Bull 133: 833–858.
Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS. (2009) 5-HT receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181–188.
Roffman JL, Marci CD, Glick DM, Dougherty DD, Rauch SL. (2005) Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol Med 35: 1385–1398.
Russo EB, Burnett A, Hall B, Parker KK. (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037–1043.
Saxena S, Brody AL, Maidment KM, Smith EC, Zohrabi N, Katz E, et al. (2004) Cerebral glucose metabolism in obsessive-compulsive hoarding. Am J Psychiatry 161: 1038–1048.
Schienle A, Schäfer A, Walter B, Stark R, Vaitl D. (2005) Brain activation of spider phobics towards disorder-relevant, generally disgust-and fear-inducing pictures. Neurosci Lett 388: 1–6.
Schneider F, Weiss U, Kessler C, Muller-Gartner HW, Posse S, Salloum JB, et al. (1999) Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol Psychiatry 45: 863–871.
Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, et al. (2009) Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14: 1040–1050.
Straube T, Mentzel HJ, Glauer M, Miltner WH. (2004) Brain activation to phobia-related words in phobic subjects. Neurosci Lett 372: 204–208.
Szeszko PR, Ardekani BA, Ashtari M, Malhotra AK, Robinson DG, Bilder RM, et al. (2005) White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry 62: 782–790.
Talairach J, Tournoux P. (1988) Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme.
Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613–623.
Trzesniak C, Araújo D, Crippa JAS. (2008) Magnetic resonance spectroscopy in anxiety disorders. Acta Neuropsychiatrica 20: 56–71.
Tung A, Bluhm B, Mendelson WB. (2001) The hypnotic effect of propofol in the medial preoptic area of the rat. Life Sci 69: 855–862.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273–289.
Van der Linden G, van Heerden B, Warwick J, Wessels C, van Kradenburg J, Zungu-Dirwayi N, et al. (2000) Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 24: 419–438.
Veltman DJ, Tuinebreijer WE, Winkelman D, Lammertsma AA, Witter MP, Dolan RJ, et al. (2004) Neurophysiological correlates of habituation during exposure in spider phobia. Psychiatry Res 132: 149–158.
Viveros MP, Marco EM, File SE. (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331–342.
Vogt BA, Finch DM, Olson CR. (1992) Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 2: 435–443.
Watanabe K, Kayano Y, Matsunaga T, Yamamoto I and Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19: 1109–1111.
Wik G, Fredrikson M, Ericson K, Eriksson L, Stone-Elander S, Greitz T. (1993) A functional cerebral response to frightening visual stimulation. Psychiatry Res 50: 15–24.
Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159: 122–128.
Zuardi AW. (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271–280.
Zuardi AW, Karniol IG. (1981) Transcultural evaluation of a self-evaluation scale of subjective states. J Bras Psiquiatr 131: 403–406.
Zuardi AW, Karniol IG. (1983) Changes in the conditioned emotional response of rats induced by Δ9-THC, CBD and mixture of the two cannabinoids. Arq Biol Tecnol 26: 391–397.
Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. (1993b) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82–88.
Zuardi A, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, et al. (2010a) Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 24: 135–137.
Zuardi AW, Crippa JA, Hallak JE. (2010b) Cannabis sativa: the plant that can induce unwanted effects and also treat them. Rev Bras Psiquiatr 32(Suppl I): S56–S66.
Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421–429.
Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, et al. (2009) Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol 23: 979–983.
Zuardi AW, Finkelfarb E, Bueno OFA, Musty RE and Karniol IG (1981) Characteristics of the stimulus produced by the mixture of cannabidiol with D9-tetrahydrocannabinol. Arch Int Pharmacodyn 249: 137–146.
Zuardi AW, Guimaraes FS, Moreira AC. (1993a) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26: 213–217.
Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56: 485–486.
Zuardi AW, Rodrigues JA, Cunha JM. (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 104: 260–264.
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76: 245–250.

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
EMAIL ARTICLE LINK
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the Sage Journals article sharing page.

Information, rights and permissions

Information

Published In

Article first published online: September 9, 2010
Issue published: January 2011

Keywords

  1. Cannabidiol
  2. CBD
  3. social anxiety
  4. regional cerebral blood flow
  5. SPECT

Rights and permissions

© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
Request permissions for this article.
PubMed: 20829306

Authors

Affiliations

José Alexandre S Crippa
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Guilherme Nogueira Derenusson
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Thiago Borduqui Ferrari
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Lauro Wichert-Ana
NCT Translational Medicine.
Fábio LS Duran
Department of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil.
Rocio Martin-Santos
Department of Psychological Medicine, Section of Neuroimaging, Institute of Psychiatry, University of London, UK.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Marcus Vinícius Simões
Division of Neurology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Sagnik Bhattacharyya
Department of Psychological Medicine, Section of Neuroimaging, Institute of Psychiatry, University of London, UK.
Paolo Fusar-Poli
Department of Psychological Medicine, Section of Neuroimaging, Institute of Psychiatry, University of London, UK.
Zerrin Atakan
Department of Psychological Medicine, Section of Neuroimaging, Institute of Psychiatry, University of London, UK.
Alaor Santos Filho
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Maria Cecília Freitas-Ferrari
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Philip K McGuire
Department of Psychological Medicine, Section of Neuroimaging, Institute of Psychiatry, University of London, UK.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Antonio Waldo Zuardi
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Geraldo F Busatto
Department of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil.
Jaime Eduardo Cecílio Hallak
Departments of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Brazil.
Medical Clinic, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.

Notes

José Alexandre S Crippa, MD, PhD, Department of Neurosciences and Behavior, Division of Psychiatry; Faculdade de Medicina de Ribeirão Preto; Universidade de São Paulo, Hospital das Clínicas - Terceiro Andar; Av. Bandeirantes, 3900; Ribeirão Preto, São Paulo, Brazil Email: [email protected]

Metrics and citations

Metrics

Journals metrics

This article was published in Journal of Psychopharmacology.

VIEW ALL JOURNAL METRICS

Article usage*

Total views and downloads: 22099

*Article usage tracking started in December 2016


Altmetric

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores



Articles citing this one

Receive email alerts when this article is cited

Web of Science: 335 view articles Opens in new tab

Crossref: 352

  1. Cannabinoids in the Treatment of Selected Mental Illnesses: Practical ...
    Go to citation Crossref Google Scholar
  2. Expectancies of the Effects of Cannabis Use in Individuals with Social...
    Go to citation Crossref Google Scholar
  3. UK Medical Cannabis Registry: a case series analyzing clinical outcome...
    Go to citation Crossref Google Scholar
  4. The NLRP3 inflammasome: a vital player in inflammation and mediating t...
    Go to citation Crossref Google Scholar
  5. Possible effects of cannabidiol (CBD) administration on the vocal acti...
    Go to citation Crossref Google Scholar
  6. Is cannabidiol (CBD) effective to ease separation anxiety?
    Go to citation Crossref Google Scholar
  7. Cannabis use in adolescents and anxiety symptoms and disorders: a syst...
    Go to citation Crossref Google Scholar
  8. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits ...
    Go to citation Crossref Google Scholar
  9. Cannabidiol and brain function: current knowledge and future perspecti...
    Go to citation Crossref Google Scholar
  10. Relationship Between Nociplastic Pain Involvement and Medication Use, ...
    Go to citation Crossref Google Scholar
  11. An Overview of Cannabidiol
    Go to citation Crossref Google Scholar
  12. The impact of cannabidiol placebo on responses to an acute stressor: A...
    Go to citation Crossref Google ScholarPub Med
  13. Daily cannabidiol and L-theanine beverage consumption does not alter a...
    Go to citation Crossref Google Scholar
  14. Effects of Cannabidiol in Adolescent and Young Adult Depressive and An...
    Go to citation Crossref Google Scholar
  15. A cohort study comparing the effects of medical cannabis for anxiety p...
    Go to citation Crossref Google Scholar
  16. Behavioral observations, heart rate and heart rate variability in hors...
    Go to citation Crossref Google Scholar
  17. Effects of cannabidiol on anandamide levels in individuals with cannab...
    Go to citation Crossref Google Scholar
  18. Naturalistic examination of the anxiolytic effects of medical cannabis...
    Go to citation Crossref Google Scholar
  19. The therapeutic potential of purified cannabidiol
    Go to citation Crossref Google Scholar
  20. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of ...
    Go to citation Crossref Google Scholar
  21. Increased hippocampal blood flow in people at clinical high risk for p...
    Go to citation Crossref Google Scholar
  22. Subjective, behavioral and neurobiological effects of cannabis and can...
    Go to citation Crossref Google Scholar
  23. The effects of cannabidiol on worry and anxiety among high trait worri...
    Go to citation Crossref Google Scholar
  24. Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Qualit...
    Go to citation Crossref Google Scholar
  25. Herbal Anxiolytics: Sources and Their Preparation Methods
    Go to citation Crossref Google Scholar
  26. Quality improvement study in epilepsy patients treated with Epidiolex®
    Go to citation Crossref Google Scholar
  27. Women are taking the hit: Examining the unique consequences of cannabi...
    Go to citation Crossref Google Scholar
  28. Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition i...
    Go to citation Crossref Google Scholar
  29. Anxiolytic effects of endocannabinoid enhancing compounds: A systemati...
    Go to citation Crossref Google Scholar
  30. Medicinal cannabis for psychiatry-related conditions: an overview of c...
    Go to citation Crossref Google Scholar
  31. An Updated Analysis of Clinical Outcome Measures Across Patients From ...
    Go to citation Crossref Google Scholar
  32. THC-Reduced Cannabis sativa L.—How Does the Solvent Determine the Bioa...
    Go to citation Crossref Google Scholar
  33. Uncovering the Importance of Peer-to-Peer Communication during the COV...
    Go to citation Crossref Google Scholar
  34. Comparing the effects of medical cannabis for chronic pain patients wi...
    Go to citation Crossref Google Scholar
  35. Multinational Association of Supportive Care in Cancer (MASCC) guideli...
    Go to citation Crossref Google Scholar
  36. THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
    Go to citation Crossref Google Scholar
  37. How long does a single oral dose of cannabidiol persist in plasma? Fin...
    Go to citation Crossref Google Scholar
  38. Scientific Validation of Cannabidiol for Management of Dog and Cat Dis...
    Go to citation Crossref Google Scholar
  39. papel da Medicina de Família e Comunidade no uso medicinal de Cannabis
    Go to citation Crossref Google Scholar
  40. Therapeutic Molecular Insights into the Active Engagement of Cannabino...
    Go to citation Crossref Google Scholar
  41. Cannabinoids to Improve Health-Related Quality of Life in Patients wit...
    Go to citation Crossref Google Scholar
  42. Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, a...
    Go to citation Crossref Google Scholar
  43. Endocannabinoid System and Exogenous Cannabinoids in Depression and An...
    Go to citation Crossref Google Scholar
  44. Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemothera...
    Go to citation Crossref Google Scholar
  45. Cannabidiol attenuates fear memory expression in female rats via hippo...
    Go to citation Crossref Google Scholar
  46. Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Sym...
    Go to citation Crossref Google Scholar
  47. THC and CBD: Similarities and differences between siblings
    Go to citation Crossref Google Scholar
  48. Cannabidiol regulates apoptosis and autophagy in inflammation and canc...
    Go to citation Crossref Google Scholar
  49. Expectancies about the effects of cannabidiol products on anxiety symp...
    Go to citation Crossref Google Scholar
  50. Therapeutic uses of Cannabis sativa L. Current state and future perspe...
    Go to citation Crossref Google Scholar
  51. Consenso colombiano del tratamiento con cannabidiol (CBD) puro en psiq...
    Go to citation Crossref Google Scholar
  52. Comparison of the Cannabinoid and Terpene Profiles in Commercial Canna...
    Go to citation Crossref Google Scholar
  53. Polydrug users, use of cannabinoids and abuse potential: A focus on ca...
    Go to citation Crossref Google Scholar
  54. Medical use of cannabidiol and impact on cancer cell viability
    Go to citation Crossref Google Scholar
  55. The safety and efficacy of low oral doses of cannabidiol: An evaluatio...
    Go to citation Crossref Google Scholar
  56. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidio...
    Go to citation Crossref Google Scholar
  57. Medical Use of Cannabinoids and Psychedelic Compounds
    Go to citation Crossref Google Scholar
  58. Newer Modalities in Psychopharmacology in Children and Adolescents: A ...
    Go to citation Crossref Google Scholar
  59. Therapeutic and clinical foundations of cannabidiol therapy for diffic...
    Go to citation Crossref Google Scholar
  60. Pharmacokinetics and Cognitive Side Effcets of Cannabidiol In Adult Pa...
    Go to citation Crossref Google Scholar
  61. Effects of cannabidiol on simulated driving and cognitive performance:...
    Go to citation Crossref Google ScholarPub Med
  62. Cannabidiol in clinical and preclinical anxiety research. A systematic...
    Go to citation Crossref Google ScholarPub Med
  63. Cannabinoid treatments for anxiety: A systematic review and considerat...
    Go to citation Crossref Google Scholar
  64. Cannabinoids and the endocannabinoid system in fibromyalgia: A review ...
    Go to citation Crossref Google Scholar
  65. Hippocampal circuit dysfunction in psychosis
    Go to citation Crossref Google Scholar
  66. Clinical and cognitive improvement following full-spectrum, high-canna...
    Go to citation Crossref Google Scholar
  67. Medical cannabinoids: a pharmacology-based systematic review and meta-...
    Go to citation Crossref Google Scholar
  68. A mixed methods analysis of cannabis use routines for chronic pain man...
    Go to citation Crossref Google Scholar
  69. Cannabinoids in the management of behavioral, psychological, and motor...
    Go to citation Crossref Google Scholar
  70. Therapeutic Effects of Cannabinoids and Their Applications in COVID-19...
    Go to citation Crossref Google Scholar
  71. Systematic literature review of human studies assessing the efficacy o...
    Go to citation Crossref Google Scholar
  72. Potential Utility of Cannabidiol in Stress-Related Disorders
    Go to citation Crossref Google Scholar
  73. Assessment of clinical outcomes of medicinal cannabis therapy for depr...
    Go to citation Crossref Google Scholar
  74. Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design an...
    Go to citation Crossref Google Scholar
  75. Maintained anxiolytic effects of cannabidiol after treatment discontin...
    Go to citation Crossref Google Scholar
  76. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medicati...
    Go to citation Crossref Google Scholar
  77. Therapeutisch gebruik van cannabidiol in volwassenpsychiatrie: stand v...
    Go to citation Crossref Google Scholar
  78. Effects of rich cannabidiol oil on behavioral disturbances in patients...
    Go to citation Crossref Google Scholar
  79. Cannabidiol for the treatment of autism spectrum disorder: hope or hyp...
    Go to citation Crossref Google Scholar
  80. Medicinal Cannabis for the Treatment of Anxiety Disorders: a Narrative...
    Go to citation Crossref Google Scholar
  81. Tetrahydrocannabinol and cannabidiol medicines for chronic pain and me...
    Go to citation Crossref Google Scholar
  82. Anticonvulsant Action and Long-Term Effects of Chronic Cannabidiol Tre...
    Go to citation Crossref Google Scholar
  83. A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Empha...
    Go to citation Crossref Google Scholar
  84. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combinat...
    Go to citation Crossref Google Scholar
  85. Do alcohol and cannabis substitute or complement each other? Analysis ...
    Go to citation Crossref Google Scholar
  86. The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeosta...
    Go to citation Crossref Google Scholar
  87. Cannabidiol enhancement of exposure therapy in treatment refractory pa...
    Go to citation Crossref Google Scholar
  88. Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot ...
    Go to citation Crossref Google Scholar
  89. Cannabidiol (CBD) treatment improves spatial memory in 14-month-old fe...
    Go to citation Crossref Google Scholar
  90. UK Medical Cannabis registry: an analysis of clinical outcomes of medi...
    Go to citation Crossref Google Scholar
  91. UK Medical Cannabis Registry: an analysis of clinical outcomes of medi...
    Go to citation Crossref Google Scholar
  92. Altered relationship between cortisol response to social stress and me...
    Go to citation Crossref Google Scholar
  93. A narrative review of molecular mechanism and therapeutic effect of ca...
    Go to citation Crossref Google Scholar
  94. The Construct of Medical and Non-Medical Marijuana—Critical Review
    Go to citation Crossref Google Scholar
  95. A scoping review of the use of cannabidiol in psychiatric disorders
    Go to citation Crossref Google Scholar
  96. The endocannabinoid system in social anxiety disorder: from pathophysi...
    Go to citation Crossref Google Scholar
  97. Cannabidiol (CBD) in Cancer Management
    Go to citation Crossref Google Scholar
  98. Often Undiagnosed but Treatable: Case Vignettes and Clinical Considera...
    Go to citation Crossref Google Scholar
  99. Cannabinoid Drugs in Mental Health Disorders
    Go to citation Crossref Google Scholar
  100. Over-The-Counter Cannabidiol (CBD)
    Go to citation Crossref Google Scholar
  101. Over-the-Counter Cannabidiol (CBD)
    Go to citation Crossref Google Scholar
  102. Nutraceutical potential of industrial hemp
    Go to citation Crossref Google Scholar
  103. Industrial hemp in animal feed applications
    Go to citation Crossref Google Scholar
  104. Clinical Approaches to Cannabis
    Go to citation Crossref Google Scholar
  105. Use of Cannabidiol (CBD) Oil in the Treatment of PTSD: Study Design an...
    Go to citation Crossref Google Scholar
  106. Effects of cannabidiol in cannabis flower: Implications for harm reduc...
    Go to citation Crossref Google Scholar
  107. Cannabidiol Product Dosing and Decision-Making in a National Survey of...
    Go to citation Crossref Google Scholar
  108. A Coala‐T‐Cannabis Survey Study of breast cancer patients' use of cann...
    Go to citation Crossref Google Scholar
  109. The Neurocognitive Effects of Cannabis Across the Lifespan
    Go to citation Crossref Google Scholar
  110. Wonder or evil?: Multifaceted health hazards and health benefits of Ca...
    Go to citation Crossref Google Scholar
  111. Cannabidiol induces autophagy via ERK1/2 activation in neural cells
    Go to citation Crossref Google Scholar
  112. THC-induced behavioral stereotypy in zebrafish as a model of psychosis...
    Go to citation Crossref Google Scholar
  113. Cannabidiol (CBD) Use among children with juvenile idiopathic arthriti...
    Go to citation Crossref Google Scholar
  114. Developmental cannabidiol exposure increases anxiety and modifies geno...
    Go to citation Crossref Google Scholar
  115. Reasons for cannabidiol use: a cross-sectional study of CBD users, foc...
    Go to citation Crossref Google Scholar
  116. Enhancing Endocannabinoid Control of Stress with Cannabidiol
    Go to citation Crossref Google Scholar
  117. The Management of Cancer Symptoms and Treatment-Induced Side Effects W...
    Go to citation Crossref Google Scholar
  118. Physiological and Cellular Targets of Neurotrophic Anxiolytic Phytoche...
    Go to citation Crossref Google Scholar
  119. The effects of pelleted cannabidiol supplementation on heart rate and ...
    Go to citation Crossref Google Scholar
  120. Pharmacological properties, therapeutic potential, and legal status of...
    Go to citation Crossref Google Scholar
  121. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older...
    Go to citation Crossref Google Scholar
  122. The Use of Marijuana Derivatives in Primary Care: An Evidence-Based Ap...
    Go to citation Crossref Google Scholar
  123. Cannabidiol for the treatment of crack-cocaine craving: an exploratory...
    Go to citation Crossref Google Scholar
  124. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an ...
    Go to citation Crossref Google Scholar
  125. Endocannabinoids, cannabinoids and the regulation of anxiety
    Go to citation Crossref Google Scholar
  126. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) produ...
    Go to citation Crossref Google Scholar
  127. Citalopram and Cannabidiol
    Go to citation Crossref Google Scholar
  128. Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in...
    Go to citation Crossref Google Scholar
  129. Practical considerations for testing the effects of cannabidiol on hum...
    Go to citation Crossref Google Scholar
  130. Potential therapeutic benefits of cannabinoid products in adult psychi...
    Go to citation Crossref Google Scholar
  131. Cannabidiol: Knowledge, Beliefs, and Experiences of Patients With Canc...
    Go to citation Crossref Google Scholar
  132. An Observational, Longitudinal Study of Cognition in Medical Cannabis ...
    Go to citation Crossref Google Scholar
  133. Optimizing the Process Design of Oil-in-Water Nanoemulsion for Deliver...
    Go to citation Crossref Google Scholar
  134. The Cream of the Crop: Biology, Breeding, and Applications of ...
    Go to citation Crossref Google Scholar
  135. The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimagin...
    Go to citation Crossref Google Scholar
  136. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment O...
    Go to citation Crossref Google Scholar
  137. Evaluation of Patient Reported Safety and Efficacy of Cannabis From a ...
    Go to citation Crossref Google Scholar
  138. Pharmakotherapie von Angsterkrankungen – leitliniengerechte Therapie u...
    Go to citation Crossref Google Scholar
  139. Cannabinoids and Pain
    Go to citation Crossref Google Scholar
  140. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of...
    Go to citation Crossref Google Scholar
  141. Feeding Cannabidiol (CBD)-Containing Treats Did Not Affect Canine Dail...
    Go to citation Crossref Google Scholar
  142. Cannabidiol induces antidepressant and anxiolytic‐like effects in expe...
    Go to citation Crossref Google Scholar
  143. A phase I trial of the safety, tolerability and pharmacokinetics of ca...
    Go to citation Crossref Google Scholar
  144. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders,...
    Go to citation Crossref Google Scholar
  145. Safety and tolerability of natural and synthetic cannabinoids in adult...
    Go to citation Crossref Google Scholar
  146. Prospects for the Use of Cannabinoids in Psychiatric Disorders
    Go to citation Crossref Google Scholar
  147. Cannabidiol treatment in an adolescent with multiple substance abuse, ...
    Go to citation Crossref Google Scholar
  148. Cannabidiol in the Treatment of Epilepsy
    Go to citation Crossref Google Scholar
  149. Targeting the Endocannabinoid System in Borderline Personality Disorde...
    Go to citation Crossref Google Scholar
  150. Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Rev...
    Go to citation Crossref Google Scholar
  151. Early life stress and development of the endocannabinoid system: A bid...
    Go to citation Crossref Google Scholar
  152. Cannabinoids in Audiogenic Seizures: From Neuronal Networks to Future ...
    Go to citation Crossref Google Scholar
  153. From an Alternative Medicine to a New Treatment for Refractory Epileps...
    Go to citation Crossref Google Scholar
  154. Glial Cells and Their Contribution to the Mechanisms of Action of Cann...
    Go to citation Crossref Google Scholar
  155. Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental...
    Go to citation Crossref Google ScholarPub Med
  156. Cannabis Use and Prospective Long-Term Association with Anxiety: A Sys...
    Go to citation Crossref Google ScholarPub Med
  157. Molecular and neurocircuitry mechanisms of social avoidance
    Go to citation Crossref Google Scholar
  158. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related An...
    Go to citation Crossref Google Scholar
  159. Psychiatric neuroimaging research in Brazil: historical overview, curr...
    Go to citation Crossref Google Scholar
  160. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adju...
    Go to citation Crossref Google Scholar
  161. The Impact of Cannabidiol on Human Brain Function: A Systematic Review
    Go to citation Crossref Google Scholar
  162. Constituents of Cannabis Sativa
    Go to citation Crossref Google Scholar
  163. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders
    Go to citation Crossref Google Scholar
  164. Well Being
    Go to citation Crossref Google Scholar
  165. Cannabinoids and Mental Health Risks
    Go to citation Crossref Google Scholar
  166. Anxiety
    Go to citation Crossref Google Scholar
  167. Cannabinoid Drugs in Mental Health Disorders
    Go to citation Crossref Google Scholar
  168. Sustainable Hemp Products
    Go to citation Crossref Google Scholar
  169. Cannabidiol: pharmacology and therapeutic targets
    Go to citation Crossref Google Scholar
  170. Putative effects of cannabidiol in depression and synaptic plasticity
    Go to citation Crossref Google Scholar
  171. Cannabidiol safety
    Go to citation Crossref Google Scholar
  172. The science behind medical marijuana and research challenges
    Go to citation Crossref Google Scholar
  173. Therapeutic Potential for Cannabinoids in Sports Medicine: Current Lit...
    Go to citation Crossref Google Scholar
  174. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment O...
    Go to citation Crossref Google Scholar
  175. “Over-the-counter” cannabidiol (CBD) sold in the community pharmacy se...
    Go to citation Crossref Google Scholar
  176. Therapeutic potential and safety considerations for the clinical use o...
    Go to citation Crossref Google Scholar
  177. A single dose of cannabidiol modulates medial temporal and striatal fu...
    Go to citation Crossref Google Scholar
  178. Impact of canine epilepsy on judgement and attention biases
    Go to citation Crossref Google Scholar
  179. Medicinal cannabis for psychiatric disorders: a clinically-focused sys...
    Go to citation Crossref Google Scholar
  180. Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a...
    Go to citation Crossref Google Scholar
  181. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic ...
    Go to citation Crossref Google Scholar
  182. Cannabidiol and Sports Performance: a Narrative Review of Relevant Evi...
    Go to citation Crossref Google Scholar
  183. The therapeutic role of Cannabidiol in mental health: a systematic rev...
    Go to citation Crossref Google Scholar
  184. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Co...
    Go to citation Crossref Google Scholar
  185. The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC...
    Go to citation Crossref Google Scholar
  186. Cannabidiol normalizes resting-state functional connectivity in treatm...
    Go to citation Crossref Google Scholar
  187. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety,...
    Go to citation Crossref Google Scholar
  188. Subacute cannabidiol alters genome‐wide DNA ...
    Go to citation Crossref Google Scholar
  189. CBD and THC: Do They Complement Each Other Like Yin and Yang?
    Go to citation Crossref Google Scholar
  190. Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart F...
    Go to citation Crossref Google Scholar
  191. Efficacy and acceptability of cannabinoids for anxiety disorders in ad...
    Go to citation Crossref Google Scholar
  192. Treatment of social anxiety disorder and attenuated psychotic symptoms...
    Go to citation Crossref Google Scholar
  193. Cannabinoids and their therapeutic applications in mental disorders

    Go to citation Crossref Google Scholar
  194. The Impact of Feeding Cannabidiol (CBD) Containing Treats on Canine Re...
    Go to citation Crossref Google Scholar
  195. Cannabis sativa L. and Its Extracts: Regulation of Canna...
    Go to citation Crossref Google Scholar
  196. The effects of acute cannabidiol on cerebral blood flow and its relati...
    Go to citation Crossref Google ScholarPub Med
  197. Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence Fr...
    Go to citation Crossref Google Scholar
  198. Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects...
    Go to citation Crossref Google Scholar
  199. Evaluation of the potential use of cannabidiol in the treatment of coc...
    Go to citation Crossref Google Scholar
  200. Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of ...
    Go to citation Crossref Google Scholar
  201. The effect of cannabidiol on simulated car driving performance: A rand...
    Go to citation Crossref Google Scholar
  202. Acute effects of cannabinoids on symptoms of obsessive‐compulsive diso...
    Go to citation Crossref Google Scholar
  203. The Milk Thistle Seed Cakes and Hempseed Cakes are Potential Feed for ...
    Go to citation Crossref Google Scholar
  204. Cannabidiol inhibits sucrose self‐administration by CB ...
    Go to citation Crossref Google Scholar
  205. Neurobiological findings underlying depressive behavior in Parkinson’s...
    Go to citation Crossref Google Scholar
  206. Two-weeks treatment with cannabidiol improves biophysical and behavior...
    Go to citation Crossref Google Scholar
  207. The effects of acute and sustained cannabidiol dosing for seven days o...
    Go to citation Crossref Google Scholar
  208. Do the effects of cannabis on the hippocampus and striatum increase ri...
    Go to citation Crossref Google Scholar
  209. Deconstructing the neurobiology of cannabis use disorder
    Go to citation Crossref Google Scholar
  210. Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredicta...
    Go to citation Crossref Google Scholar
  211. High-Frequency Medical Cannabis Use Is Associated With Worse Pain Amon...
    Go to citation Crossref Google Scholar
  212. Cannabidiol as a Treatment for Mood Disorders: A Systematic Review: Le...
    Go to citation Crossref Google ScholarPub Med
  213. Clinical uses of cannabis and cannabinoids in the United States
    Go to citation Crossref Google Scholar
  214. Cannabidiol prescription in clinical practice: an audit on the first 4...
    Go to citation Crossref Google Scholar
  215. Immune Responses Regulated by Cannabidiol
    Go to citation Crossref Google Scholar
  216. Cannabinoids for the treatment of mental disorders
    Go to citation Crossref Google Scholar
  217. Cannabinoids for the treatment of mental disorders – Author's reply
    Go to citation Crossref Google Scholar
  218. Differentiating Medicinal and Recreational Cannabis Users via Cannabis...
    Go to citation Crossref Google Scholar
  219. The relationship between psychological health and social support: Evid...
    Go to citation Crossref Google Scholar
  220. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Tre...
    Go to citation Crossref Google Scholar
  221. Cannabis in Palliative Medicine
    Go to citation Crossref Google Scholar
  222. Cannabis and Neuropsychiatric Effects
    Go to citation Crossref Google Scholar
  223. Affective Disorders
    Go to citation Crossref Google Scholar
  224. Respiratory depression following an accidental overdose of a CBD-label...
    Go to citation Crossref Google Scholar
  225. Use of cannabidiol in anxiety and anxiety-related disorders
    Go to citation Crossref Google Scholar
  226. New Targeted Treatments for Fragile X Syndrome
    Go to citation Crossref Google Scholar
  227. Therapeutic strategies for social anxiety disorder: where are we now?
    Go to citation Crossref Google Scholar
  228. Cannabinoids for the treatment of mental disorders and symptoms of men...
    Go to citation Crossref Google Scholar
  229. How does cannabidiol (CBD) influence the acute effects of delta-9-tetr...
    Go to citation Crossref Google Scholar
  230. Novel pharmacological targets in drug development for the treatment of...
    Go to citation Crossref Google Scholar
  231. Real life Experience of Medical Cannabis Treatment in Autism: Analysis...
    Go to citation Crossref Google Scholar
  232. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With...
    Go to citation Crossref Google Scholar
  233. Examination of a New Delivery Approach for Oral Cannabidiol in Healthy...
    Go to citation Crossref Google Scholar
  234. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Dr...
    Go to citation Crossref Google Scholar
  235. Cannabis Use Preferences and Decision-making Among a Cross-sectional C...
    Go to citation Crossref Google Scholar
  236. Modulation of the Endocannabinoid and Oxytocinergic Systems as a Poten...
    Go to citation Crossref Google Scholar
  237. Clinicians’ Guide to Cannabidiol and Hemp Oils
    Go to citation Crossref Google Scholar
  238. Cannabidiol (CBD) use in psychiatric disorders: A systematic review
    Go to citation Crossref Google Scholar
  239. Cannabidiol: A budding industry!
    Go to citation Crossref Google Scholar
  240. A systematic review of cannabidiol dosing in clinical populations
    Go to citation Crossref Google Scholar
  241. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psy...
    Go to citation Crossref Google Scholar
  242. Cannabidiol attenuates aggressive behavior induced by social isolation...
    Go to citation Crossref Google Scholar
  243. Cannabinoids-Human Physiology and Agronomic Principles for Production
    Go to citation Crossref Google Scholar
  244. Denying renal transplantation to an adolescent medical cannabis user: ...
    Go to citation Crossref Google Scholar
  245. Emerging evidence for the antidepressant effect of cannabidiol and the...
    Go to citation Crossref Google Scholar
  246. fMRI study of cannabidiol-induced changes in attention control in trea...
    Go to citation Crossref Google Scholar
  247. Higher odds of irritable bowel syndrome among hospitalized patients us...
    Go to citation Crossref Google Scholar
  248. Cannabinoid Regulation of Fear and Anxiety: an Update
    Go to citation Crossref Google Scholar
  249. Single and combined effects of plant‐derived and synthetic cannabinoid...
    Go to citation Crossref Google Scholar
  250. Cannabis use behaviors and prevalence of anxiety and depressive sympto...
    Go to citation Crossref Google Scholar
  251. Psychosocial and Pharmacological Interventions for the Treatment of Ca...
    Go to citation Crossref Google Scholar
  252. Cannabidiol as a suggested candidate for treatment of autism spectrum ...
    Go to citation Crossref Google Scholar
  253. A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differenti...
    Go to citation Crossref Google Scholar
  254. Is there a role for cannabidiol in psychiatry?
    Go to citation Crossref Google Scholar
  255. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease s...
    Go to citation Crossref Google Scholar
  256. Cannabidiol presents an inverted U-shaped dose-response curve in a sim...
    Go to citation Crossref Google Scholar
  257. Cannabidiol as a potential treatment for psychosis
    Go to citation Crossref Google ScholarPub Med
  258. Cannabidiol and Cannabis Use Disorder
    Go to citation Crossref Google Scholar
  259. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review o...
    Go to citation Crossref Google Scholar
  260. Cannabidiol – decades of research and current clinical uses
    Go to citation Crossref Google Scholar
  261. Management of chronic pain with Jalaprakshalana (water-wash) Shodhita ...
    Go to citation Crossref Google Scholar
  262. Cannabidiol modulates serotonergic transmission and reverses both allo...
    Go to citation Crossref Google Scholar
  263. Cannabidiol effects on prepulse inhibition in nonhuman primates
    Go to citation Crossref Google Scholar
  264. Nuclear Neuroimaging in Social Anxiety Disorder: A Review
    Go to citation Crossref Google Scholar
  265. New Perspectives on the Use of Cannabis in the Treatment of Psychiatri...
    Go to citation Crossref Google Scholar
  266. Cannabinoids in health and disease: pharmacological potential in metab...
    Go to citation Crossref Google Scholar
  267. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
    Go to citation Crossref Google Scholar
  268. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfu...
    Go to citation Crossref Google Scholar
  269. Medical Use of Cannabinoids
    Go to citation Crossref Google Scholar
  270. Translational Investigation of the Therapeutic Potential of Cannabidio...
    Go to citation Crossref Google Scholar
  271. Unique treatment potential of cannabidiol for the prevention of relaps...
    Go to citation Crossref Google Scholar
  272. Are cannabis-using and non-using patients different groups? Towards un...
    Go to citation Crossref Google ScholarPub Med
  273. Pharmacological properties of cannabidiol in the treatment of psychiat...
    Go to citation Crossref Google Scholar
  274. A Cross-Sectional Study of Cannabidiol Users
    Go to citation Crossref Google Scholar
  275. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cann...
    Go to citation Crossref Google Scholar
  276. Cannabis regulatory science: risk–benefit considerations for mental di...
    Go to citation Crossref Google Scholar
  277. Resting regional brain metabolism in social anxiety disorder and the e...
    Go to citation Crossref Google Scholar
  278. The Endocannabinoid System, Aggression, and the Violence of Synthetic ...
    Go to citation Crossref Google Scholar
  279. The effects of cannabidiol on persecutory ideation and anxiety in a hi...
    Go to citation Crossref Google ScholarPub Med
  280. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-...
    Go to citation Crossref Google Scholar
  281. Neurocognitive effects of cannabis: Lessons learned from human experim...
    Go to citation Crossref Google Scholar
  282. Psychosocial and pharmacological interventions for the treatment of ca...
    Go to citation Crossref Google Scholar
  283. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
    Go to citation Crossref Google Scholar
  284. A Systematic Review of the Effectiveness of Medical Cannabis for Psych...
    Go to citation Crossref Google Scholar
  285. Is cannabis treatment for anxiety, mood, and related disorders ready f...
    Go to citation Crossref Google Scholar
  286. Cannabidiol regulation of emotion and emotional memory processing: rel...
    Go to citation Crossref Google Scholar
  287. Cannabis, cannabinoids, and health
    Go to citation Crossref Google Scholar
  288. Cannabidiol: State of the art and new challenges for therapeutic appli...
    Go to citation Crossref Google Scholar
  289. Cannabidiol in medical marijuana: Research vistas and potential opport...
    Go to citation Crossref Google Scholar
  290. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetr...
    Go to citation Crossref Google Scholar
  291. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cann...
    Go to citation Crossref Google Scholar
  292. Neuroimaging studies towards understanding the central effects of phar...
    Go to citation Crossref Google Scholar
  293. Neuronal and molecular effects of cannabidiol on the mesolimbic dopami...
    Go to citation Crossref Google Scholar
  294. A Systematic Review and Meta-Analysis of the Haemodynamic Effects of C...
    Go to citation Crossref Google Scholar
  295. Medical cannabis and mental health: A guided systematic review
    Go to citation Crossref Google Scholar
  296. The Cannabinoid System in Nicotine Dependence and Withdrawal
    Go to citation Crossref Google Scholar
  297. The Endocannabinoid System and Anxiety
    Go to citation Crossref Google Scholar
  298. Evidence for the use of “medical marijuana” in psychiatric and neurolo...
    Go to citation Crossref Google Scholar
  299. The Anxiolytic Effects of Cannabidiol (CBD)
    Go to citation Crossref Google Scholar
  300. The Use of Medical Marijuana in the Treatment of Psychiatric Disorders
    Go to citation Crossref Google Scholar
  301. Cannabidiol for the Treatment of Drug Use Disorders
    Go to citation Crossref Google Scholar
  302. A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use an...
    Go to citation Crossref Google Scholar
  303. Cannabis: From Cultivar to Chemovar II—A Metabolomics Approach to Cann...
    Go to citation Crossref Google Scholar
  304. Targeting the Endocannabinoid System in Psychiatric Illness
    Go to citation Crossref Google Scholar
  305. Cannabidiol Modulates Fear Memory Formation Through Interactions with ...
    Go to citation Crossref Google Scholar
  306. Medicinal Uses of Marijuana and Cannabinoids
    Go to citation Crossref Google Scholar
  307. Alcohol and cannabis use among college students: Substitutes or comple...
    Go to citation Crossref Google Scholar
  308. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiov...
    Go to citation Crossref Google Scholar
  309. A Review of Recent Advances in the Therapeutic Uses of Secondary Canna...
    Go to citation Crossref Google Scholar
  310. Overlapping Mechanisms of Stress-Induced Relapse to Opioid Use Disorde...
    Go to citation Crossref Google Scholar
  311. Clinical/Therapeutic Approaches for Cannabinoid Ligands in Central and...
    Go to citation Crossref Google Scholar
  312. Screening Medications for the Treatment of Cannabis Use Disorder
    Go to citation Crossref Google Scholar
  313. Gene × Environment Interactions in Schizophrenia: Evidence from Geneti...
    Go to citation Crossref Google Scholar
  314. Developmental regulation of fear learning and anxiety behavior by endo...
    Go to citation Crossref Google Scholar
  315. Addressing the stimulant treatment gap: A call to investigate the ther...
    Go to citation Crossref Google Scholar
  316. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allo...
    Go to citation Crossref Google Scholar
  317. Early Phase in the Development of Cannabidiol as a Treatment for Addic...
    Go to citation Crossref Google Scholar
  318. Cannabidiol as a Potential Treatment for Anxiety Disorders
    Go to citation Crossref Google Scholar
  319. Safety and Toxicology of Cannabinoids
    Go to citation Crossref Google Scholar
  320. A nutraceutical role for cannabidiol. Why not?
    Go to citation Crossref Google Scholar
  321. Dissociation between the panicolytic effect of cannabidiol microinject...
    Go to citation Crossref Google Scholar
  322. Scientific Opinion on the risks for human health related to the presen...
    Go to citation Crossref Google Scholar
  323. Safety and Pharmacokinetics of Oral Cannabidiol When Administered Conc...
    Go to citation Crossref Google Scholar
  324. Investigational drugs for anxiety in patients with schizophrenia
    Go to citation Crossref Google Scholar
  325. Effects of minocycline add-on treatment on brain morphometry and cereb...
    Go to citation Crossref Google Scholar
  326. The role of endocannabinoid function in posttraumatic stress disorder
    Go to citation Crossref Google Scholar
  327. Interaction Between L-Type Calcium Channels and Antagonist of Cannabin...
    Go to citation Crossref Google Scholar
  328. What we know and do not know about the cannabinoid receptor 2 (CB2)
    Go to citation Crossref Google Scholar
  329. Policy designs for cannabis legalization: starting with the eight Ps
    Go to citation Crossref Google Scholar
  330. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy a...
    Go to citation Crossref Google Scholar
  331. Neuroendocrinology and Neuroimaging Studies of Social Anxiety Disorder
    Go to citation Crossref Google Scholar
  332. Effects of Cannabis and Cannabinoids in the Human Nervous System
    Go to citation Crossref Google Scholar
  333. Variability of cannabis potency in the Venice area (Italy): A survey o...
    Go to citation Crossref Google Scholar
  334. Is cannabis neurotoxic for the healthy brain? A meta‐analytical review...
    Go to citation Crossref Google Scholar
  335. Differential Effect of Orexin-1 and CRF-1 Antagonism on Stress Circuit...
    Go to citation Crossref Google Scholar
  336. Cannabidiol reduces cigarette consumption in tobacco smokers: Prelimin...
    Go to citation Crossref Google Scholar
  337. Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Ne...
    Go to citation Crossref Google Scholar
  338. Endocannabinoid system and mood disorders: Priming a target for new th...
    Go to citation Crossref Google Scholar
  339. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluat...
    Go to citation Crossref Google Scholar
  340. Weeding out the information: an ethnographic approach to exploring how...
    Go to citation Crossref Google Scholar
  341. Multiple mechanisms involved in the large-spectrum therapeutic potenti...
    Go to citation Crossref Google Scholar
  342. Cannabis, a complex plant: different compounds and different effects o...
    Go to citation Crossref Google ScholarPub Med
  343. Pharmacological treatment of anxiety disorders: Current treatments and...
    Go to citation Crossref Google Scholar
  344. Failure to extinguish fear and genetic variability in the human cannab...
    Go to citation Crossref Google Scholar
  345. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
    Go to citation Crossref Google Scholar
  346. Cannabidiol in Humans—The Quest for Therapeutic Targets
    Go to citation Crossref Google Scholar
  347. Phytocannabinoids as novel therapeutic agents in CNS disorders
    Go to citation Crossref Google Scholar
  348. Pharmacological interventions in the treatment of the acute effects of...
    Go to citation Crossref Google Scholar
  349. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid ...
    Go to citation Crossref Google Scholar
  350. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking i...
    Go to citation Crossref Google Scholar

Figures and tables

Figures & Media

Tables

View Options

Get access

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:


Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Access journal content via a DeepDyve subscription or find out more about this option.

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text